Displaying 71–80 of 152 news results
Apr 29, 2021
Foundation Fighting Blindness and Usher 1F Collaborative to Launch Natural History Study
The project will help identify outcome measures for future clinical trials of potential USH1F therapies.
Apr 27, 2021
Foundation Fighting Blindness Appoints Claire M. Gelfman, Ph.D. as Chief Scientific Officer
Dr. Gelfman brings over twenty years of successful ophthalmic research and development experience to the Foundation executive team.
Mar 23, 2021
Foundation Fighting Blindness Launches Chapter Program Rebrand
The program honors Lulie Gund and her legacy and commitment to the Foundation’s Chapter community.
Mar 2, 2021
Foundation Fighting Blindness To Jointly Host Online Continuing Medical Education (CME, COPE) Webinar
Course Title: Clinical Trials of Emerging Therapies for Retinal Degeneration Patients: Hope and Opportunities
Feb 4, 2021
Dr Daniel C. Chung appointed as Chief Medical Officer of SparingVision
Former Spark Therapeutics head of ophthalmic medical affairs, responsible for the development and approval of Luxturna™, to lead development of SparingVision’s proprietary asset, SPVN06, and further pipeline development
Feb 3, 2021
Foundation Insights Forum – January 29, 2021
The Foundation Fighting Blindness is pleased to provide a recording and full transcript of the Insights Forum, our quarterly conference call providing updates to the inherited retinal disease community. The call took place on January 29, 2021.
Jan 29, 2021
Renowned Pioneers in Ophthalmology Join SparingVision’s Scientific Advisory Board
Development of lead asset SPVN06 to further benefit from high-level Clinical Advisory Board
Jan 26, 2021
Kevin Nealon Hosts Foundation Fighting Blindness’ Experiential Event – Hope from Home: A United Night to Save Sight
In honor of Rare Disease Day, this February 28th virtual event will raise awareness and fund research leading to treatments and cures for blinding retinal diseases.
Dec 16, 2020
Atsena Therapeutics Raises $55 Million Series A Financing to Advance LCA1 Gene Therapy Clinical Program, Two Preclinical Assets, and Novel Capsid Development for Ocular Diseases
Round was led by Sofinnova Investments with participation from Abingworth, Lightstone Ventures and all existing investors.
Company expands board of directors and plans to build out team.
Dec 14, 2020
Kodi Lee Teams up with Foundation Fighting Blindness and Two Blind Brothers for Music to our Eyes Livestream Music Series
This December 17th exclusive conversation and acoustic performance by Kodi Lee of America’s Got Talent will raise awareness and funds to find treatments and cures for blinding diseases.